PD1 antibody

DRUG4 trials

Sponsors

HRYZ Biotech Co., Beijing Friendship Hospital, Fudan University

Conditions

Advanced Gastric CancerAdvanced Solid TumorsEBV InfectionEndometrial CancerFertility

Phase 1

A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors

TerminatedNCT03034304

HRYZ Biotech Co.Advanced Solid Tumors

Start: 2017-02-22End: 2023-11-13Updated: 2025-07-24

A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor

HRYZ Biotech Co.Advanced Gastric Cancer

Start: 2018-04-19End: 2020-07-31Target: 28Updated: 2019-08-29

Phase 2

Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification

RecruitingNCT07319429

Fudan UniversityEndometrial Cancer, Fertility

Start: 2026-01-25End: 2029-12-31Target: 260Updated: 2026-03-13

Phase 3

PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV

Beijing Friendship HospitalEBV Infection

Start: 2019-09-15End: 2022-07-01Target: 40Updated: 2022-01-05

Related Papers

Long-term results of multi-antigen stimulated cell therapy-I, alone or in combination with chemotherapy, as first-line maintenance therapy in advanced sarcoma: a multicenter, phase 1 trial.

2026-08-03

Updated results on multiple antigens stimulating cellular therapy (MASCT-I) in metastatic urothelial carcinoma: A randomized, open-label, phase I trial.

Journal of Clinical Oncology2024-06-01

Multiple antigen stimulating cellular therapy (MASCT)-I for metastatic urothelial carcinoma (mUC): A multicenter, phase I study (MASCT-I-1001).

Journal of Clinical Oncology2023-06-01

A phase I study to evaluate the safety of multiantigen stimulated tumor specific cell therapy (MASCT-I) in subjects with advanced gastric cancer.

Journal of Clinical Oncology2021-01-203 citations